Is Semaglutide Available on the NHS for Weight Loss?

What NICE's guidance on NHS semaglutide actually requires

NICE published its recommendation for semaglutide (Wegovy) in March 2023 under technology appraisal TA875. The recommendation is genuine, but it comes with conditions that rule out the majority of people who enquire about it.

To qualify under NICE TA875, a patient must be an adult with a BMI of 35 or above and at least one weight-related comorbidity, things like type 2 diabetes, high blood pressure, obstructive sleep apnoea, or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the thresholds are 2.5 kg/m² lower throughout. A BMI of 27–34.9 may qualify only where a specialist-referral pathway is already in place. Crucially, treatment must be delivered within a specialist weight management service offering multidisciplinary support, and NICE caps NHS semaglutide at a maximum of two years.

Stop-point criteria also apply: if a patient hasn't lost at least 5% of their starting weight after six months on the full maintenance dose, continuing is reviewed. That's a meaningful clinical gate, not a formality.

The upshot is that a GP cannot simply prescribe Wegovy off the back of a standard appointment. Even patients who meet the BMI and comorbidity thresholds still need to be referred into a specialist service, and those services have waiting lists. For a closer look at how the NHS rollout is unfolding, the picture of when Wegovy becomes available on the NHS is changing year by year.

Why NHS access remains limited in practice

The gap between NICE recommending a medicine and patients being able to access it on the NHS is a familiar one in UK healthcare. Wegovy is no exception. Specialist weight management services in England are unevenly distributed, consistently oversubscribed, and (in many areas) operating waiting lists of a year or longer.

The NHS England guidance on weight-management injections sets out the wraparound care requirements: every patient receiving semaglutide on the NHS should be supported by dietary advice, physical activity guidance, and psychological input where needed. That's the right clinical model. It also means the service can only expand as fast as those wraparound components can be resourced, which is not quickly.

Scotland, Wales and Northern Ireland each run their own access pathways, with different thresholds and service structures. If you're based in Scotland, the availability of Wegovy on the NHS in Scotland follows devolved criteria worth checking separately.

None of this is criticism of the NHS. It reflects what happens when a clinically significant medicine meets a healthcare system with finite capacity. The honest answer for many people is that the NHS route, even if they qualify in theory, will involve a wait they're not prepared to take.

The private prescription route: what it involves and what to check

A private prescription for semaglutide is the legal alternative for people who don't meet NHS criteria, or who meet them but can't wait. The medicine is identical, Wegovy, the same licensed brand, from the same UK-authorised supply chain. What differs is the funding and the setting.

Private providers range from GPhC-registered online pharmacies to private clinics. Before using any of them, check the pharmacy's registration on the GPhC register, a five-second step that confirms you're dealing with a regulated business. Unregistered sellers offering semaglutide without a clinical assessment are operating illegally, and the MHRA has warned repeatedly about counterfeit pens circulating online. If you're unsure whether you'd qualify or how the process works, our wegovy prescription assistance guidance walks through what to expect at each stage. It's also worth reading up on whether semaglutide is available on the NHS for weight loss before deciding which route suits your circumstances.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber the same day, the assessment lands on a clinician's desk, not an algorithm's queue. If clinically suitable, treatment is dispatched the same day for free next-working-day delivery in plain packaging. One transparent price covers the consultation, prescription, medicine and delivery; there are no subscriptions and no auto-renewals. If you'd like to understand what private treatment typically costs before going further, the cost context for Wegovy in the UK is worth reading first.

The full Wegovy treatment overview covers everything from how semaglutide works to what the clinical trial evidence shows. When you're ready to discuss your own situation, speak to our prescribers through a free consultation.